Literature DB >> 16498592

The management of insulinoma.

O N Tucker1, P L Crotty, K C Conlon.   

Abstract

BACKGROUND: Insulinomas are rare tumours. Their clinical presentation, localization techniques and operative management were reviewed.
METHODS: An electronic search of the Medline, Embase and Cochrane databases was undertaken for articles published between January 1966 and June 2005 on the history, presentation, clinical evaluation, use of imaging techniques for tumour localization and operative management of insulinoma. RESULTS AND
CONCLUSION: Most insulinomas are intrapancreatic, benign and solitary. Biochemical diagnosis is obtained during a supervised 72-h fast. Non-invasive preoperative imaging techniques to localize lesions continue to evolve. Intraoperative ultrasonography can be combined with other preoperative imaging modalities to improve tumour detection. Surgical resection is the treatment of choice. In the absence of preoperative localization and intraoperative detection of an insulinoma, blind pancreatic resection is not recommended. Copyright (c) 2006 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498592     DOI: 10.1002/bjs.5280

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  45 in total

1.  A new frameshift MEN1 gene mutation associated with familial malignant insulinomas.

Authors:  Shirin Hasani-Ranjbar; Mahsa M Amoli; Azadeh Ebrahim-Habibi; Mohammad Hossein Gozashti; Nahid Khalili; Forugh A Sayyahpour; Jila Hafeziyeh; Akbar Soltani; Bagher Larijani
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

Review 2.  Diagnosis and management of insulinoma.

Authors:  Takehiro Okabayashi; Yasuo Shima; Tatsuaki Sumiyoshi; Akihito Kozuki; Satoshi Ito; Yasuhiro Ogawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

3.  Laparoscopic enucleation of pancreatic neoplasm.

Authors:  A Dedieu; A Rault; D Collet; B Masson; A Sa Cunha
Journal:  Surg Endosc       Date:  2010-07-10       Impact factor: 4.584

Review 4.  Non-surgical ablative therapies for inoperable benign insulinoma.

Authors:  C Mele; A Brunani; B Damascelli; V Tichà; L Castello; G Aimaretti; M Scacchi; P Marzullo
Journal:  J Endocrinol Invest       Date:  2017-07-28       Impact factor: 4.256

5.  Early detection of cognitive impairment in patients with insulinoma.

Authors:  Hongmei Dai; Hao Chen; Xiafei Hong; Xianlin Han; Qiang Xu; Haiyu Pang; Jing Yuan; Xianze Wang; Peiran Xu; Jialin Jiang; Rui Jiang; Zhe Zhuang; Yupei Zhao; Wenming Wu
Journal:  Endocrine       Date:  2019-07-10       Impact factor: 3.633

6.  Sporadic Insulinoma Presenting as Early Morning Night Terrors.

Authors:  Daniel Beisang; Gregory P Forlenza; Mark Luquette; Kyriakie Sarafoglou
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

7.  Accurate preoperative localization of insulinomas avoids the need for blind resection and reoperation: analysis of a single institution experience with 17 surgically treated tumors over 19 years.

Authors:  Brian K P Goh; London L P J Ooi; Peng-Chung Cheow; Yu-Meng Tan; Hock-Soo Ong; Yaw-Fui A Chung; Pierce K H Chow; Wai-Keong Wong; Khee-Chee Soo
Journal:  J Gastrointest Surg       Date:  2009-03-17       Impact factor: 3.452

8.  Enucleation of pancreatic cystadenomas.

Authors:  Chunlin Ge; Xiaoguang Luo; Xuchun Chen; Kejian Guo
Journal:  J Gastrointest Surg       Date:  2009-09-25       Impact factor: 3.452

Review 9.  Occult sporadic insulinoma: localization and surgical strategy.

Authors:  Bassam Abboud; Joe Boujaoude
Journal:  World J Gastroenterol       Date:  2008-02-07       Impact factor: 5.742

10.  Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer.

Authors:  Timothy R Donahue; Kevork K Kazanjian; William H Isacoff; Howard A Reber; O Joe Hines
Journal:  J Gastrointest Surg       Date:  2010-03-23       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.